Phase 2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Tacrolimus × Clear all
NCT04904588 2026-03-18

ACCESS

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
300 enrolled
NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
204 enrolled
NCT06001385 2026-02-05

OPTIMIZE

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
313 enrolled
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
NCT01760655 2025-10-30

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
62 enrolled 15 charts
NCT05031897 2025-10-30

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

Phase 2 Recruiting
63 enrolled
NCT02790515 2025-08-12

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
170 enrolled
NCT02220985 2025-06-04

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Fred Hutchinson Cancer Center

Phase 2 Completed
84 enrolled
NCT01350245 2025-05-16

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Thomas Jefferson University

Phase 2 Completed
28 enrolled 10 charts
NCT03096782 2023-10-11

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
6 enrolled 10 charts
NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
NCT01246206 2018-06-18

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
21 enrolled 13 charts
NCT02877082 2018-04-30

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Emory University

Phase 2 Terminated
5 enrolled 10 charts
NCT01621477 2017-02-20

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

St. Jude Children's Research Hospital

Phase 2 Terminated
34 enrolled 12 charts
NCT00787761 2012-10-01

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Northside Hospital, Inc.

Phase 2 Completed
24 enrolled 13 charts